Connection

Gavin Screaton to Humans

Back to Details
This is a "connection" page, showing publications Gavin Screaton has written about Humans.
Gavin Screaton
Connection Strength
0.101
Humans
  1. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021 08 05; 184(16):4220-4236.e13.
    View in: PubMed
    Score: 0.008
  2. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021 04 29; 184(9):2348-2361.e6.
    View in: PubMed
    Score: 0.007
  3. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell. 2021 04 15; 184(8):2201-2211.e7.
    View in: PubMed
    Score: 0.007
  4. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell. 2021 04 15; 184(8):2183-2200.e22.
    View in: PubMed
    Score: 0.007
  5. The immune response against flaviviruses. Nat Immunol. 2018 11; 19(11):1189-1198.
    View in: PubMed
    Score: 0.006
  6. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine. Cold Spring Harb Perspect Biol. 2018 06 01; 10(6).
    View in: PubMed
    Score: 0.006
  7. Evolution of neurovirulent Zika virus. Science. 2017 11 17; 358(6365):863-864.
    View in: PubMed
    Score: 0.006
  8. Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response. Nat Immunol. 2017 Nov; 18(11):1228-1237.
    View in: PubMed
    Score: 0.006
  9. The immunopathology of dengue and Zika virus infections. Curr Opin Immunol. 2017 10; 48:1-6.
    View in: PubMed
    Score: 0.006
  10. Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. Nat Commun. 2017 05 23; 8:15411.
    View in: PubMed
    Score: 0.006
  11. Recent advances in human flavivirus vaccines. Curr Opin Virol. 2017 04; 23:95-101.
    View in: PubMed
    Score: 0.006
  12. The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers. Clin Infect Dis. 2021 08 02; 73(3):e699-e709.
    View in: PubMed
    Score: 0.002
  13. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021 08; 8(8):e474-e485.
    View in: PubMed
    Score: 0.002
  14. T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nat Commun. 2021 04 06; 12(1):2055.
    View in: PubMed
    Score: 0.002
  15. A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. Nat Commun. 2021 03 29; 12(1):1951.
    View in: PubMed
    Score: 0.002
  16. Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections. BMC Infect Dis. 2021 Feb 18; 21(1):187.
    View in: PubMed
    Score: 0.002
  17. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med. 2021 02 11; 384(6):533-540.
    View in: PubMed
    Score: 0.002
  18. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfus Med. 2021 Jun; 31(3):167-175.
    View in: PubMed
    Score: 0.002
  19. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Euro Surveill. 2020 10; 25(42).
    View in: PubMed
    Score: 0.002
  20. SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. Euro Surveill. 2020 10; 25(42).
    View in: PubMed
    Score: 0.002
  21. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 2020 11; 21(11):1336-1345.
    View in: PubMed
    Score: 0.002
  22. Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. Elife. 2020 08 21; 9.
    View in: PubMed
    Score: 0.002
  23. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol. 2020 10; 27(10):950-958.
    View in: PubMed
    Score: 0.002
  24. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell Host Microbe. 2020 09 09; 28(3):445-454.e6.
    View in: PubMed
    Score: 0.002
  25. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine. J Virol. 2018 12 01; 92(23).
    View in: PubMed
    Score: 0.002
  26. Endothelial Nitric Oxide Pathways in the Pathophysiology of Dengue: A Prospective Observational Study. Clin Infect Dis. 2017 Oct 16; 65(9):1453-1461.
    View in: PubMed
    Score: 0.001
  27. The open reading frame 3a protein of severe acute respiratory syndrome-associated coronavirus promotes membrane rearrangement and cell death. J Virol. 2010 Jan; 84(2):1097-109.
    View in: PubMed
    Score: 0.001
  28. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008 Oct 15; 181(8):5490-500.
    View in: PubMed
    Score: 0.001
  29. Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. Nat Genet. 2006 Jan; 38(1):38-46.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.